Home / Market News / $CAH
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

UBS Adjusts Cardinal Health Price Target to $310 From $295

Nov 6, 2026, 7:07 PM UTC · Primary ticker $CAH

UBS has increased its price target for Cardinal Health to $310 from $295, while maintaining a 'Buy' rating. This update reflects an analyst's revised valuation following the company's recent earnings, suggesting a positive outlook for the stock.

UBS updated its financial outlook for Cardinal Health, increasing its price target from $295 to $310 and reiterating a 'Buy' rating. This action follows the company's recent quarterly earnings release, indicating that UBS analysts have processed the latest financial performance and adjusted their valuation accordingly. For traders, this represents a positive signal from a prominent investment bank, potentially leading to increased investor confidence and short-term buying interest in Cardinal Health shares. While not a direct company action, an analyst upgrade from a firm like UBS can influence market sentiment and provide a tailwind for the stock, especially if other analysts follow suit. The long-term implications depend on whether the company's fundamentals continue to support such valuations.

$CAH positive Price target increase by major analyst
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.